The Vanderbilt Urologic Oncology Fellowship is accredited by the Society of Urologic Oncology (SUO) and was established in 2007. The fellowship is designed to prepare leaders in academic Urologic Oncology. Vanderbilt is a high-volume regional and national referral center for comprehensive genitourinary cancer care. There are currently six fellowship-trained Urologic Oncologists on faculty at Vanderbilt who bring varied backgrounds, interests, and prior training to the fellowship program.
The Vanderbilt fellowship was founded by Dr. Joseph A. Smith, Jr., Chairman of the Department of Urologic Surgery. The Fellowship Program Director is Dr. Sam S. Chang, who oversees the clinical and didactic components of the training program. The clinical urologic oncology faculty includes Drs. Daniel A. Barocas, Peter E. Clark, David F. Penson, and Matthew J. Resnick. Collectively, they possess a wealth of clinical training and expertise, including the most current laparoscopic, robotic-assisted laparoscopic, and ablative techniques. Each faculty member is actively engaged in clinical and/or translational research as evidenced by the impact of Vanderbilt publications and grants awarded to current faculty members. In addition, Vanderbilt urologic oncology faculty are well represented in national and international committees and are actively involved at the highest level of organizational urology. Examples of Vanderbilt faculty leadership include participation in the American Urological Association (AUA) clinical guidelines on Advanced Prostate Cancer, Noninvasive Bladder Cancer, various National Comprehensive Cancer Center (NCCN) guidelines, as well as chairing GU staging for the American Joint Committee on Cancer. In addition, Vanderbilt urologic oncology faculty lead the AUA Health Policy and SUO Fellowship committees. The faculty are committed to education as evidenced by participation in the AUA/ABU examination committee and the SUO Oncology Knowledge Assessment Examination (OKAT). They are also well represented on the editorial staff of important journals including the Journal of Urology and Cancer. In addition to the clinical and administrative activities, there are five research laboratories in the department run by four independently funded PhD scientists and one MD, with consistent excellence in grant funding, research publication and training of fellows.
The Vanderbilt University Medical Center is a world-class institution, ranked 15th in NIH research funding for 2012 having been awarded 588 awards comprising $213,727,910. The Medical Center is home to a variety of clinical, academic and research resources, including the NCI-accredited Vanderbilt-Ingram Cancer Center and the Vanderbilt Institute for Clinical and Translational Research (VICTR).
The objectives of the Fellowship are consistent with the goals of the SUO accrediting body. The Fellowship aims to provide comprehensive training in the evaluation and management of urologic malignancies, as well as the tools to evaluate and contribute to the research in this field. Specifically, the Fellow will acquire advanced expertise in the multidisciplinary management of urologic cancers, including the ability to apply the critical principles of radiation oncology, medical oncology, urologic imaging and pathology. The Fellow will also acquire advanced understanding of the biology of urologic malignancies through clinical experiences, self-directed learning, the Urologic Oncology curriculum, and research endeavors. The Fellows will learn the important aspects of study design, biostatistics, clinical trials, data analysis, scientific methodology and laboratory research.
The Fellowship is a minimum of two years in length, with the first year dedicated to clinical training and the second year dedicated to research. The focus of the clinical year is the development of surgical skills and clinical acumen. The surgical training is intensive and includes hands-on experience in open surgery, laparoscopy, robotic and energy-ablative techniques. One day each week is spent in the clinic, learning the intricacies of the multidisciplinary management of urologic cancers.
In the second year, the Fellow will initiate a research project under the guidance of a research mentor. The aims are to acquire research skills that can be applied to a career in academic Urologic Oncology and to make impactful contributions to the care of patients with urologic cancers. Many fellows will work in one of the department’s research laboratories. Possible mentors include Simon Hayward, PhD, Robert Matusik, PhD, and Peter Clark, MD. Dr. Hayward’s lab has substantial expertise in stromal-epithelial interactions in prostate cancer as well as prostate cancer xenografts. Dr. Matusik’s research focus in on androgen regulation of gene expression, and his lab has developed novel transgenic mouse models for prostate cancer. Dr. Clark is a prototypical “surgeon scientist” with research interests in Wilms’ Tumor and Renal Cell Carcinoma. His lab has developed a novel transgenic mouse model of Wilms’ Tumor.
Some fellows may elect to pursue health services research, working within the Center for Surgical Quality and Outcomes Research, directed by David Penson, MD, MPH. Dr. Penson is Principal Investigator of the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study on prostate cancer and was awarded a $7.6 million dollar stimulus grant for the study. Daniel Barocas, MD, MPH, is a co-investigator on this study and is another member of the Urology faculty with expertise in health services research. Additionally, Matthew Resnick, MD has a unique interest in policy-relevant health services research and works closely with Drs. Penson and Barocas.
Throughout the two year program, the Fellow will play an active role in tumor board conferences and the didactic lecture series, as well as the multidisciplinary “cancer club” conference. These conferences provide a framework for learning the biology of urologic cancers and a stimulus for further investigation.
Admission is contingent upon completion of an ACGME accredited urologic training program. Accordingly, applicants must have taken or be registered to take the qualifying portion (Part I) of the American Board of Urology exam or be board certified by the ABU.
Application to the Fellowship in Urologic Oncology should be made at least 19 months prior to the completion of residency (i.e., by March 1 of the year preceding the chief residency year). Interested candidates should forward a copy of their CV, personal statement and 2 letters of reference including a letter of support from their program director and an additional letter from a faculty member recommending them for the fellowship and attesting to the candidate's successful completion of the urology training program.
Letters should be addressed to Sam S. Chang, MD, Fellowship Program Director, Department of Urologic Surgery, A1302 MCN, Nashville, TN 37232 or email at email@example.com with a copy michele.clark@Vanderbilt.Edu
Any inquiries or questions may be directed to Michele Clark at michele.clark@Vanderbilt.Edu